Vaxfab Enterprises Limited has successfully completed a significant capital raising exercise through the preferential allotment of warrants and equity shares. The Board of Directors approved this strategic move on January 12, 2026, marking a substantial expansion of the company's equity base.

Warrant Allotment Details

The company allotted 2,04,04,371 fully convertible warrants to investors on a preferential basis. These warrants carry specific terms and conditions designed to provide flexibility to both the company and investors.

The warrants are convertible into equivalent fully paid-up equity shares at the option of allottees within the specified timeframe. Upon conversion, the resulting equity shares will rank pari-passu with existing equity shares of the company.

Equity Share Conversion

Simultaneously, the company completed the conversion of 21,27,689 warrants into equity shares. This conversion represents the exercise of previously outstanding warrants by existing warrant holders.

The conversion process involved 41 investors who exercised their warrants at the predetermined price. The warrant exercise price structure included ₹5.26 paid at the time of initial warrant allotment and ₹15.77 paid at conversion.

Impact on Share Capital

Following these transactions, Vaxfab Enterprises experienced a significant increase in its paid-up equity share capital. The company's capital structure has been strengthened through this preferential allotment process.

Investor Participation

The allotment attracted diverse participation from individual investors and corporate entities. Major warrant allocations included significant investments from limited liability partnerships and individual investors. Notable allocations ranged from 47,574 warrants to 1,998,097 warrants per investor, demonstrating varied investment levels across the investor base.

The successful completion of both warrant allotment and equity conversion reflects strong investor confidence in the company's prospects. All participating investors fall under the public category, indicating broad-based interest in the company's growth story. The Board meeting commenced at 8:00 PM and concluded at 8:30 PM on January 12, 2026, efficiently completing the approval process for these significant corporate actions.

Vaxfab enterprises Limited has successfully completed a significant capital raising exercise through the allotment of fully convertible warrants and equity shares on a preferential basis. The Board of Directors approved these allotments during their meeting held on January 12, 2026, marking a substantial fundraising milestone for the Ahmedabad-based company.

Warrant Allotment Details

The company allotted 2,04,04,371 fully convertible warrants to 50 investors at ₹21.02 per warrant. These warrants carry conversion rights within a maximum period of 18 months from the allotment date, allowing holders to convert them into equivalent fully paid-up equity shares of ₹10 face value each.

The warrant allotment includes both individual investors and institutional entities. Major allocations went to entities such as Vintage Diamond LLP (19,02,950 warrants), Sparkling Tradewing LLP (19,98,097 warrants), and Markand Tradeventure LLP (19,55,281 warrants), alongside numerous individual investors.

Equity Share Conversion

Simultaneously, the company allotted 21,27,689 equity shares to 41 investors upon conversion of previously issued warrants. The conversion was executed at the same price of ₹21.02 per share, with investors paying the balance amount of ₹15.765 per warrant (having already paid ₹5.255 at the time of initial warrant allotment).

Notable conversions included Mitesh Dineshbhai Patel and Seema Miteshkumar Patel, who each converted 3,09,229 warrants into equity shares, and Suresh Jethalal Dama, who converted 1,90,294 warrants while retaining one unconverted warrant.

Impact on Share Capital

Following these allotments, Vaxfab Enterprises' paid-up equity share capital increased significantly. The company's total paid-up capital now stands at ₹10,52,76,890, comprising 1,05,27,689 equity shares of ₹10 face value each. The newly allotted equity shares rank pari-passu with existing equity shares, providing equal rights and privileges to all shareholders.

Regulatory Compliance

The allotments were conducted in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive disclosures including investor details, allotment specifics, and post-allotment shareholding patterns as required under SEBI guidelines. The Board meeting commenced at 8:00 PM and concluded at 8:30 PM on January 12, 2026, with Managing Director Ravindra Ashokbhai Joshi overseeing the proceedings.